Scancell Advances iSCIB1+ to Phase III for Advanced Melanoma

Scancell has chosen its immunotherapy candidate iSCIB1+ for Phase III development following encouraging Phase II results. The iSCIB1+ Immunobody, when used alongside Yervoy (ipilimumab) and Opdivo (nivolumab), achieved a 68.6% overall response rate in patients with advanced, unresectable melanoma — significantly higher than the 50% response rate reported in the Checkmate 067 trial with checkpoint inhibitors alone. In the Phase II SCOPE trial, iSCIB1+ also improved progression-free survival (PFS), with 80.8% of patients showing no disease progression at 11 months, compared to 43.9% at 12 months for the standard Yervoy-Opdivo combo. The study initially compared both SCIB1 and iSCIB1+, but the SCIB1 arm was halted due to evolving standards of care. With the current standard therapies offering limited durability and response, iSCIB1+ presents a promising alternative for improving outcomes. Scancell now plans to launch a global registrational Phase III trial targeting advanced melanoma patients.

28-07-2025